ArticlePLoS neglected tropical diseases2019
Longitudinal follow up of serological response in children treated for Chagas disease.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 56 citations in OpenAlex.
- Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).Antimicrobial agents and chemotherapy · 2023Trial
- Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).PLoS neglected tropical diseases · 2021Trial
- Effectiveness of benznidazole in the treatment of Chagas disease in children and adults: a long-term retrospective cohort study.Antimicrobial agents and chemotherapy · 2026Article
- Scalable Access to N‑Acylindole Linkages: Enabling the Synthesis of Antitrypanosomal Noncanonical Cyclic Peptides for Chagas Disease.Angewandte Chemie (International ed. in English) · 2026Article
- RIG-I-Adjuvanted Immunogen Elicited T-Cell Immunity Controls Trypanosoma cruzi, Chagasic Cardiomyopathy, and Left Ventricular Dysfunction.JACC. Basic to translational science · 2026Article
- Conjugates of α-d-Galp-(1→3)-β-d-Galp for the serological diagnosis of Chagas disease.PLoS neglected tropical diseases · 2026Article
- Target product profile for the development of pediatric formulations of new drugs for the treatment of children with T. cruzi infection.PLoS neglected tropical diseases · 2026Review
- Cost-effectiveness analysis of screening for congenital Chagas disease in a non-endemic area.Nature communications · 2025Article
- Diagnosing Chagas in Pregnancy and Childhood: What's Old and New.Clinics in laboratory medicine · 2025Review
- Adverse events associated with benznidazole treatment for Chagas disease in children and adults.British journal of clinical pharmacology · 2024Article
- Why Treat Chronic Forms of Chagas Disease with Benznidazole if Adverse Reactions are Very Frequent?Arquivos brasileiros de cardiologia · 2024Article
- An α-Gal antigenic surrogate as a biomarker of treatment evaluation in Trypanosoma cruzi-infected children. A retrospective cohort study.PLoS neglected tropical diseases · 2024Article
- Efficacy of short-course treatment for prevention of congenital transmission of Chagas disease: A retrospective cohort study.PLoS neglected tropical diseases · 2024Article
- Five-year serological and clinical evolution of chronic Chagas disease patients in Cochabamba, Bolivia.PLoS neglected tropical diseases · 2023Observational
- Population pharmacokinetics of benznidazole in neonates, infants and children using a new pediatric formulation.PLoS neglected tropical diseases · 2023Article
- Chagas disease treatment efficacy markers: experiences from a Phase III study with nifurtimox in children.Frontiers in parasitology · 2023Article
- Clinical use of molecular methods forFrontiers in parasitology · 2023Article
- Long-term cardiology outcomes in children after early treatment for Chagas disease, an observational study.PLoS neglected tropical diseases · 2022Observational
- Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults.Antimicrobial agents and chemotherapy · 2022Article
- Pediatric Chagas disease in the non-endemic area of Madrid: A fifteen-year review (2004-2018).PLoS neglected tropical diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvaluation of therapeutic response in chronic Chagas disease is a major challenge, due to prolonged persistence of Trypanosoma cruzi-specific antibodies, lack of sensitivity of parasitological tests, and need for long-term follow-up to observe negative seroconversion of conventional serological tests (CS). The objective of this study was to evaluate F2/3-ELISA serology, a promising early biomarker of therapeutic response, and T.cruzi Polymerase chain reaction (PCR) for T. cruzi Deoxyribonucleic acid (DNA), for neonatal diagnosis and evaluation of parasitemia after treatment.
methodsProspective cohort study, with three-year clinical, serological and parasitological follow-up of pediatric Chagas disease patients treated with benznidazole. Serology was evaluated by Enzyme-Linked ImmunoSorbent Assay (ELISA), Indirect hemagglutination (IHA) and F2/3-ELISA; Parasitemia by microhematocrit (MH) and PCR.
resultsA cohort of 107 pediatric patients treated with benznidazole was enrolled in the study. ELISA and IHA were initially reactive in 100% of patients, F2/3-ELISA serology was reactive in 80% (86/107) and 91% (97/107) had detectable parasitemia. Seventy-six (71%) patients completed at least 36 months of serological follow up after treatment. Although a similar decreasing linear trend was observed for all serological tests, F2/3-ELISA presented earlier, age dependent, negative seroconversion compared to CS. All patients reaching undetectable CS titers had previously seroreverted by F2/3-ELISA. All patients with persistently decreasing antibody titers had negative PCRs throughout the follow up period. No new cardiological lesions were observed during the 3 years follow-up period.
conclusionsThe data reported here, using CS, F2/3 ELISA and PCR provide support for the efficacy of benznidazole in congenital Chagas diseases. These results provide support for scaling up of screening, diagnosis and access to benznidazole treatment.
trial registrationClinicalTrials.gov 0028/04 in the Research Council, Secretary of Health Buenos Aires city Goberment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.